Top Page
Ondine Biomedical, Inc.
(LSE:OBI)
Ondine Biomedical, Inc. (OBI) vs. iShares MSCI United Kingdom ETF (EWC)
Ondine Biomedical, Inc. Business Overview & Revenue Model
Ondine Biomedical, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.63M | 2.05M | 1.20M | 638.00K | 2.57M | 1.79M |
| Gross Profit | 433.01K | 1.32M | 703.00K | 287.00K | 1.25M | 649.00K |
| EBITDA | -13.93M | -18.49M | -13.79M | -18.85M | -48.36M | -14.56M |
| Net Income | -14.26M | -19.10M | -14.41M | -19.37M | -50.09M | -16.27M |
Balance Sheet | ||||||
| Total Assets | 4.03M | 12.82M | 5.73M | 16.57M | 34.14M | 2.63M |
| Cash, Cash Equivalents and Short-Term Investments | 1.22M | 9.77M | 2.98M | 13.13M | 30.36M | 626.00K |
| Total Debt | 351.00K | 168.00K | 541.00K | 896.00K | 739.00K | 31.46M |
| Total Liabilities | 4.01M | 5.95M | 3.65M | 4.92M | 4.48M | 36.46M |
| Stockholders Equity | 19.00K | 6.88M | 2.08M | 11.64M | 29.66M | -33.81M |
Cash Flow | ||||||
| Free Cash Flow | -5.27M | -15.50M | -13.83M | -16.66M | -12.62M | -6.43M |
| Operating Cash Flow | -12.40M | -15.49M | -13.65M | -16.34M | -12.54M | -6.33M |
| Investing Cash Flow | -10.07K | -10.00K | -177.00K | -311.00K | -77.00K | 2.90M |
| Financing Cash Flow | 9.28M | 21.74M | 3.79M | -275.00K | 41.90M | 3.83M |
Ondine Biomedical, Inc. Technical Analysis
Ondine Biomedical, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £5.16M | -4.90 | -5.41% | ― | -20.31% | -19.35% | |
47 Neutral | £20.71M | -6.25 | -101.07% | ― | ― | 45.70% | |
40 Underperform | £41.08M | -12.70 | ― | ― | 1557.07% | 24.70% | |
38 Underperform | £64.80M | ― | ― | ― | 63.25% | 8.94% |
Ondine Biomedical, Inc. Corporate Events
Ondine Biomedical Inc. has announced a pilot program at the Royal Papworth Hospital NHS Foundation Trust to integrate its Steriwave nasal photodisinfection therapy into cardiac surgical care pathways. This initiative aims to enhance patient safety and surgical outcomes by reducing surgical site infections, particularly in the context of rising antimicrobial resistance. The pilot positions Royal Papworth among a growing list of cardiac centers adopting pre-surgical nasal photodisinfection protocols, with previous implementations showing significant reductions in infections. The Steriwave technology offers a rapid, non-antibiotic solution that does not induce resistance, making it a valuable tool in infection prevention strategies.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Ondine Biomedical Inc. reported significant commercial expansion and clinical progress in the first half of 2025, with a 41% increase in the adoption of its Steriwave® technology across hospitals, including major Canadian and NHS sites. The company is advancing its largest clinical program, a U.S. Phase 3 trial, to support FDA submission, and has completed its first ICU-based Steriwave trial, indicating potential for broader clinical application in critical care. Financially, Ondine saw an 18% increase in revenue to $1.01 million, though operational losses rose due to trial costs. The company secured additional capital, strengthening its financial position, and is focused on expanding its market presence and operational capabilities to support long-term growth.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Ondine Biomedical Inc. announced that The Mater Hospital in North Sydney has adopted its Steriwave nasal photodisinfection technology to combat antimicrobial resistance (AMR) in cancer care. This move addresses the heightened risk of drug-resistant infections among cancer patients, particularly those undergoing treatments like chemotherapy and surgery. Steriwave offers a non-invasive, cost-effective solution that reduces infection rates and supports uninterrupted cancer therapies, highlighting its potential to improve patient outcomes and ease healthcare burdens.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Ondine Biomedical Inc. announced it will release its unaudited interim financial results for the period ending 30 June 2025 on 26 September 2025. A live presentation of the results will be conducted by Dr. Nicolas Loebel and Alan Thomas, which is open to all existing and potential shareholders. This announcement provides an opportunity for stakeholders to gain insights into the company’s financial performance and strategic direction, potentially impacting investor confidence and market positioning.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Ondine Biomedical Inc. presented significant findings at the ICPIC 2025 conference, demonstrating the economic and health benefits of its Steriwave nasal photodisinfection technology. The analysis, conducted by the York Health Economics Consortium, showed that using Steriwave could reduce surgical site infections (SSIs) by over 40,000 annually in the UK, resulting in potential cost savings of over £190 million. This innovation not only improves patient outcomes by significantly reducing infection rates compared to existing treatments like Octenisan and mupirocin but also offers substantial economic value by decreasing hospital readmissions and extended stays.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Ondine Biomedical Inc. has announced that its Steriwave photodisinfection technology is 99.9% effective against the drug-resistant fungus C. auris, which has seen a 67% increase in cases in EU hospitals over the last year. This development is significant as C. auris poses a major threat to healthcare systems due to its resistance to most disinfectants and high mortality rate, with the potential to incur substantial costs in containment and treatment. Ondine’s technology offers a promising solution to manage the rising burden of invasive fungal infections, which have become a growing public health concern worldwide.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Ondine Biomedical Inc. has announced the grant of 300,000 options to a key consultant, allowing them to subscribe for new common shares at an exercise price of 15.50 pence. These options will vest over three years and can be exercised within eight years, contributing to a total of 18,863,334 options outstanding, which represents 3.64% of the company’s current issued share capital.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Ondine Biomedical’s Steriwave nasal photodisinfection technology was recently featured on CNBC’s Worldwide Exchange, where former Mexican President Vicente Fox highlighted its potential in addressing global antibiotic resistance, particularly in developing nations. The feature underscores Ondine’s leadership in non-antibiotic infection-prevention solutions and aligns with their mission to combat multidrug-resistant infections worldwide. This media attention supports the company’s strategic initiative, Light Against AMR, aimed at deploying affordable, light-based infection control technologies in underserved markets.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Ondine Biomedical Inc. has been invited to present its health economic data on Steriwave nasal photodisinfection at the International Conference on Prevention & Infection Control (ICPIC) 2025 in Geneva. The presentation will demonstrate how Steriwave significantly reduces costs associated with surgical site infections, improving patient outcomes and offering substantial savings for healthcare systems. This recognition highlights Ondine’s commitment to advancing infection control with cost-effective solutions, reinforcing its position in the healthcare industry.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Ondine Biomedical Inc. announced a correction to its total voting rights, stating that the company’s issued and fully paid share capital will consist of 518,366,964 Common Shares, rather than the previously stated 517,566,964. This adjustment is significant for shareholders as it affects the denominator used for calculating their interest in the company under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Ondine Biomedical Inc. announced the successful completion of a fundraising initiative, generating approximately £11.0 million in gross proceeds. The funds will be used to support a Phase 3 clinical trial, commercial growth, production, and operations, extending the company’s cash runway through the first half of 2026. The fundraising saw significant participation from existing shareholders and directors, underscoring confidence in the company’s strategic direction.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Ondine Biomedical Inc. announced a proposed fundraising of approximately £11 million to support its strategic initiatives, including a Phase 3 clinical trial and commercial growth efforts. The fundraising will involve a placing and subscription of new common shares, with company directors participating in the subscription. The funds are expected to extend the company’s cash runway through the first half of 2026. In the first half of 2025, Ondine focused on clinical programs and commercial expansion, achieving a 41% increase in facility adoption of its Steriwave product and an 18% revenue growth, setting a strong foundation for future growth.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Ondine Biomedical Inc. has announced the launch of a pilot program for its Steriwave nasal photodisinfection system at the ABC Medical Center in Mexico City, marking its first hospital deployment in Mexico. This initiative aims to reduce surgical site infections and healthcare-associated infections, addressing the critical challenge of antimicrobial resistance in Mexico’s private healthcare sector, which is pivotal for high-income citizens and medical tourism.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Ondine Biomedical Inc. has launched the ‘Light Against AMR Initiative’ in collaboration with the International Photodynamic Association, aiming to accelerate the adoption of photodisinfection technologies in underserved and emerging markets. The initiative is chaired by former Mexican President Vicente Fox, who will leverage his experience in healthcare access to combat antimicrobial resistance (AMR), a growing global health crisis. This strategic collaboration seeks to establish photodisinfection as a cost-effective, scalable alternative to antibiotics, particularly in regions with limited healthcare infrastructure, and aims to unite various stakeholders to overcome access barriers.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.